Cyclacel Pharmaceuticals (NASDAQ: CYCC) is a development-stage biopharmaceutical company dedicated to the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious diseases. Cyclacel’s strategy is to build a diversified biopharmaceutical business focused in hematology and…
Bullish Archived Articles
DARA Poised to Break Out on Catalysts
DARA Biosciences (NASDAQ: DARA) is expecting to hear soon on the status of its Orphan Drug application submitted to The Food and Drug Administration (FDA) in November of last year for its drug KRN5500, which is being studied for the…
Additional DD on Pozen: PA8140
The low dose version of PA32540 is called PA8140. PA8140 is not listed in their pipeline or on their website — from company’s latest 10Q: The FDA indicated that it will make a final determination during the NDA review. Based on…
UPDATED: EnteroMedics (ETRM) Basic DD and Thesis
EnteroMedics Inc. (ETRM) I bought a nice amount of shares. Catalyst trade run up target opinion: $.4.40. Positive data release: Gap to $7. 1 year: $15 (my opinions only) According to company press releases, conference calls, and my correspondence with…
Weekend Update: $CORT $ATHX $CLSN $BLRX $NEPT + Chart Analysis And Explanation
In this video, I review a couple of charts, and review a couple of my trade calls. Chart analysis and explanation offered. Hope you find the video educational! Scott
Athersys: Upcoming Short Term Catalyst With Promising Longer Term Potential
In 2012, many stem cell stocks experienced fast-paced growth as new and promising research continues to propel the industry forward. Last July, I wrote about Pluristem Therapeutics (PSTI), a bio-therapeutics company engaged in the commercialization of non-personalized cell therapy products…
CORRECTED CHARTS: Chart and commentary on $ATHX and others + Trading Technicals
Please excuse the green bed sheet in the background. We were trying different techniques for effects and obviously it did not work! Charts and Commentary on $ATHX and others.. Honoring Dr. King by following his example of looking at a…
Athersys, Inc. (ATHX) Beginning Due Diligence (chart technicals to come in seperate post)
Beginning points of Due Diligence for Athersys (ATHX) I am long the stock from $1.24. My Short Term catalyst Price Target opinion is $1.55 to $1.75, and $2.75 based on if positive Phase II data is reported. Multiple 2013 Catalysts…
Midweek Biopharma Update – $BLRX $PATH $NEPT and others + Twitter bashers (Video)
Midweek Biopharma Update – $BLRX $PATH $NEPT and others + Twitter bashers commentary. YouTube Video, enjoy!
Neptune’s Bounce Should Continue: $3 in range
Originally posted at www.biomedreports.com Updated by StockMatusow.com Twitter @BioMedReports @ScottMatusow Neptune Technologies & Bioressources announced they will hold a conference call on Thursday, January 17th at 4:30 EST. The reason given for the call will be to discuss the third…
